alexa A Better Path To Biomarker Validation: Using MALDI Mass Spec
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Conference on Translational & Personalized Medicine
August 05-07, 2013 Holiday Inn Chicago-North Shore, IL, USA

Mark Duncan
ScientificTracks Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.008
Abstract
In industry?s quest to develop novel, targeted therapies and diagnostics, the majority of potential new products stall out in the discovery phase, never reaching the patients who could benefit. Circulating proteins provide a wealth of information, however today?s standard technologies for analyzing the serum proteome come with many drawbacks, particularly in translating biomarker knowledge into clinically useful tools. The solution can be found using a proven technique that offers practical advantages to customary methods of extracting relevant information from patients? blood: MALDI-ToF mass spectrometry (MALDI). The MALDI platform can discover unique protein signatures that identify patients likely to benefit from specific therapies, and it does not require companies to shift platforms as they move from discovery to development and commercialization. Illustrating how this can be done, Biodesix Inc. of Boulder, Colo., shares insights as one of the first companies to successfully develop MALDI into a reproducible, high-throughput tool to routinely measure protein abundance from serum samples, independent of the existence of immunoassays. The company, founded on a mission of personalizing medicine, has commercialized a serum proteomic test called VeriStrat that?s capable of predicting whether patients with advanced lung-cancer will respond to the targeted second-line therapy, erlotinib (Tarceva?). In this presentation, the audience will learn about the MALDI platform approach and how it can increase their clinical success by coordinating biomarker discovery and subsequent companion diagnostic development with drug development. This novel and practical strategy for biomarker-based diagnostic development can play a central role in the creation and commercialization of new personalized therapies.
Biography
Mark Duncan is presently the Professor of Medicine at the University of Colorado and also holds the position of Director of Academic Collaborations at Biodesix, Inc.,
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version